Rocket Lab expects to resume Electron launches before year-end after September failure

Rocket Lab expects to resume Electron launches before year-end after September failure


An Electron rocket launches the Baby Come Back mission from New Zealand on July 17, 2023.

Rocket Lab

Rocket Lab expects to resume launches of its Electron vehicle before the end of the year, the company announced Wednesday.

The company is in the final stages of closing an investigation into its most recent Electron launch, which failed midflight in September. The Federal Aviation Administration, which is overseeing Rocket Lab’s failure investigation, authorized the company to resume Electron launches from its facility in New Zealand.

“Our investigation team with FAA oversight has worked around the clock since the moment of the anomaly to uncover all possible root causes, replicate them in test, and determine a path for corrective actions to avoid similar failure modes in future. We look forward to sharing the details of the review once it is fully complete,” Rocket Lab CEO Peter Beck said in a statement.

Rocket Lab stock rose about 5% in after-hours trading from its close at $4.09 a share.

Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

The company expects its review “to be completed in the coming weeks.”

The September launch was Rocket Lab’s 41st of an Electron vehicle. The company ranks as the second-most active U.S. orbital rocket launcher after SpaceX.

Rocket Lab is scheduled to report third-quarter results after markets close Nov. 8.

Don’t miss these CNBC PRO stories:



Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More